Most pertinently, significant efforts are currently underway to develop PADI4 inhibitors for the treatment of rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, thrombosis, sepsis, irritable bowel syndrome, and colon cancer (Lewis and Nacht, 2016). This evidence concerns the gene PADI4 and systemic lupus erythematosus.